Chris Twitty

Dr. Twitty brings over 25 years of life science research and drug development experience to Skye.

Dr. Twitty has led R&D and translational efforts to expand drug pipelines and supported multiple IND filings for novel therapeutics. He has additionally contributed to CMC, non-clinical, regulatory, and clinical development efforts necessary to initiate clinical trials. He has significant experience in biomarker discovery and clinical biomarker strategies. Dr. Twitty was most recently Chief Scientific (“CSO”) at Onchilles Pharma. Prior to that, he was Director and Head of Clinical Sciences and then VP of R&D and CSO at Oncosec Medical. He began his career at Bayer and also worked in research at Cell Genesys and Tocagen. He is a co-author of 19 publications and a named inventor on three patents. Dr. Twitty holds a Ph.D. Molecular Microbiology and Immunology from Oregon Health Sciences University. He was a post-doctoral fellow with the Earle A. Chiles Research Institute.